EMA Authorised: Silapo (epoetin zeta) — Stada Arzneimittel AG

View source ↗

Summary

The EMA authorises Silapo (epoetin zeta) by Stada Arzneimittel AG for treating anemia associated with cancer, chronic kidney failure, and blood transfusion reha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Blood Transfusion Autologous
• Cancer
• Kidney Failure Chronic

Drugs mentioned

• Silapo (epoetin zeta)

Snippet

Status: Authorised. Therapeutic area: Anemia;Blood Transfusion, Autologous;Cancer;Kidney Failure, Chronic. MAH: Stada Arzneimittel AG. Decision date: 31/07/2026